![]() |
||||||||||||||||||||||
|
||||||||||||||||||||||
|
||||||||||||||||||||||
| Kits | HEMOCLOT Quanti V-L | |||||||||||||||||||||
![]() |
HEMOCLOT Quanti. V-L (ACK065L) kit is a clotting method proposed for measuring Factor V-L (Factor V Leiden) concentration in citrated plasma, by its resistance to the action of Activated Protein C (APC). The assay is performed in the presence of Activated Protein C. In presence of APC and Protein S (in excess), the prolongation of clotting time is directly related to the concentration of Normal Factor V, and inversely related to the amount of Factor V-Leiden (mutation R506Q).<order now> |
|||||||||||||||||||||
Assay Characteristics
510k Application is in progress |
||||||||||||||||||||||
| Calibrators | Factor V-L Calibrator | Product Details | ||||||||||||||||||||
![]() |
Lyophilized, prediluted human plasmas, at defined Factor V-Leiden (FV-L)concentrations, for the calibration of Factor V-L activity quantitative clotting assay on human citrated plasma, using the HEMOCLOT Quanti. V-L kit (ref ACK065K). <order now> 510k Application is in progress |
|||||||||||||||||||||
| Controls | BIOPHEN Normal Control Plasma | Product Details | ||||||||||||||||||||
![]() |
Normal plasma for the quality control of assays for Protein C, Antithrombin, Factor VIII:C and Factors VII+X. The exact concentration and the acceptance ranges for each factor are indicated on the flyer provided with each kit. <order now> 510k cleared for in vitro medical diagnostic testing |
|||||||||||||||||||||
| BIOPHEN Act PC-r Control Plasma | Product details | |||||||||||||||||||||
Plasma presenting an Activated Protein C Resistance (heterozygous). <order now> 510k Application is in progress |
||||||||||||||||||||||
| CLOTTING METHOD | CEPHEN |
|||||||||||||||||||||
Aniara offers a full line of coagulation reagents, and deficient plasmas, for assays using the clotting technology. This line is expanding, and new products are continuously being introduced. We specially propose clotting assays for cofactors (such as Factor VII+X), designed with highly purified factors. The HEMOCLOT line of assays is being developed with reference to the present understanding of mechanisms, which regulate coagulation, and take advantage of the most recent technological advances for preparing the active principles required for manufacturing these kits. Therefore, proteins and enzymes used in these assays are highly purified, offer a high stability following reconstitution of the freeze-dried reagents, and allow obtaining an optimized reactivity. This actualized approach ensures excellent performances of the assays, and a good reproducibility from series to series, and from lot to lot. The HEMOCLOT line of assays can be used in manual methods, or with semi-automatic instruments or automates such as STA, STA-R, BCS, BCT, Sysmex, ACL; etc. |
Liquid reagent, ready to use, for the determination of Activated Partial Thromboplastin Time (APTT) on citrated human plasma, using a manual, semi automated or automated clotting method. |
|||||||||||||||||||||
| Purchase Products: | ||||||||||||||||||||||
|
||||||||||||||||||||||
| FIBRIPHEN |
||||||||||||||||||||||
| Clotting tests for the quatitative determination of Fibrinogen. | ||||||||||||||||||||||
| Purchase Products: | ||||||||||||||||||||||
|
||||||||||||||||||||||
|
||||||||||||||||||||||
| Downloads |
Downloads |
|||||||||||||||||||||
|
||||||||||||||||||||||
|
||||||||||||||||||||||